Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
RPX7009 (beta-lactamase inhibitor) is being studies in combination with a carbapenem biapenem
to treat bacterial infections, including those due to multi-drug resistant bacteria.
Phase:
Phase 1
Details
Lead Sponsor:
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)